HC Wainwright Weighs in on I-Mab's Q1 Earnings (NASDAQ:NBP)

Key Points

• HC Wainwright cut its Q1 2026 EPS estimate for I‑Mab to ($0.12) from ($0.07) but kept a Buy rating and a $9.00 price target, and published loss forecasts through FY2030.
• I‑Mab reported ($0.30) EPS
• Institutional ownership is significant at 38.38%, and Taikang Asset Management bought a new position of 128,765 shares (~0.11% stake) in Q4.

I-Mab (NASDAQ:NBP - Free Report) - Equities research analysts at HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for shares of I-Mab in a note issued to investors on Wednesday, April 8th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($0.12) per share for the quarter, down from their previous forecast of ($0.07). HC Wainwright has a "Buy" rating and a $9.00 price objective on the stock. HC Wainwright also issued estimates for I-Mab's Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at ($1.00) EPS, FY2028 earnings at ($1.04) EPS, FY2029 earnings at ($0.94) EPS and FY2030 earnings at ($0.71) EPS.

I-Mab (NASDAQ:NBP - Get Free Report) last posted its quarterly earnings results on Tuesday, April 7th. The company reported ($0.30) EPS for the quarter.

NBP has been the subject of several other research reports. Wall Street Zen cut I-Mab from a "buy" rating to a "hold" rating in a report on Saturday, March 21st. Weiss Ratings started coverage on I-Mab in a report on Thursday, February 5th. They issued a "sell (d-)" rating for the company. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $9.00.

I-Mab Stock Performance

I-Mab stock opened at $2.43 on Friday. The firm has a 50 day moving average price of $2.98. The firm has a market cap of $280.15 million, a PE ratio of -6.75 and a beta of 1.74. I-Mab has a 12 month low of $0.63 and a 12 month high of $6.79.

Hedge Funds Weigh In On I-Mab

An institutional investor recently bought a new position in I-Mab stock. Taikang Asset Management Hong Kong Co Ltd bought a new position in shares of I-Mab (NASDAQ:NBP - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 128,765 shares of the company's stock, valued at approximately $512,000. Taikang Asset Management Hong Kong Co Ltd owned 0.11% of I-Mab at the end of the most recent reporting period. Hedge funds and other institutional investors own 38.38% of the company's stock.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.